Seattle-based biotech firm Vedana Therapeutics has successfully closed a $46 million Series A financing round, a significant infusion of capital…
Read More
AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The European Hematology Association (EHA)…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Pioneer Novel Genetic Medicines for Kidney Diseases
Eli Lilly and Company, a global pharmaceutical leader, has significantly bolstered its commitment to the cutting-edge field of genetic medicines…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Revolutionize Kidney Disease Treatment Through Advanced Genetic Medicine
Eli Lilly and Company has announced a significant research collaboration and licensing agreement with Ascidian Therapeutics, a pioneering biotechnology firm…
Read More
Autobahn Therapeutics Secures FDA Fast Track Designation for Elunetirom in Bipolar Depression
Autobahn Therapeutics has announced a significant milestone in its development of elunetirom, a novel central nervous system (CNS)-directed thyroid hormone…
Read More
Bayer Acquires Perfuse Therapeutics for Up to $2.45 Billion to Bolster Ophthalmology Pipeline with Novel Endothelin Receptor Antagonist
Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More
BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read More
Seaport Therapeutics and Hemab Therapeutics Set for Major Public Offerings as Biotech IPO Market Gains Momentum
Seaport Therapeutics and Hemab Therapeutics are poised to join the ranks of publicly traded companies, with both biopharmaceutical firms announcing…
Read More
Eli Lilly Acquires Ajax Therapeutics for Up to $2.3 Billion in Strategic Move to Bolster Oncology Pipeline
Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read MoreYOU MAY HAVE MISSED
